Corbus Shares Advance as Pipeline Progress Takes Center Stage

Strong Cash Position Supports Ambitious Plans

Corbus Pharmaceuticals shares edged higher in after-hours trading, reaching $9.93 after closing at $9.74?a gain of nearly 2 percent. Investor attention remains fixed on the company’s latest quarterly results and, more significantly, advancements within its clinical development pipeline.

The biotechnology firm reported a second-quarter 2025 net loss of $17.7 million, a figure that exceeded analyst expectations. Operating expenses climbed to $19.2 million, primarily driven by increased clinical development activities.

Despite these losses, Corbus maintains a substantial financial cushion. With $116.6 million in cash and investments, the company is funded through the second quarter of 2027. This robust capital position provides significant runway for its ambitious research and development initiatives.

Key Upcoming Catalysts in Oncology Programs